23/10/2017 https://www.medscape.

com/viewarticle/886993_print

www.medscape.com

Delafloxacin an Effective Option for Acute Bacterial Skin Infections

By Reuters Staff

October 16, 2017

NEW YORK (Reuters Health) - Delafloxacin is non-inferior to vancomycin plus aztreonam for treating acute bacterial skin
and skin-structure infections (ABSSSI), according to a new phase 3 trial.

Delafloxacin offers the potential for the treatment of infections caused by Gram-positive pathogens including MRSA and
Gram-negative pathogens, without the need for combination therapy, Dr. Sue Cammarata of Melinta Therapeutics in
Lincolnshire, Illinois, and colleagues state in their report, online October 5 in the Journal of Antimicrobial Chemotherapy.

The U.S. Food and Drug Administration approved delafloxacin for treating ABSSSI this June. Sold as Baxdela, the drug is a
quinolone, but has a different size, shape and charge profile from other medications in this class, Dr. Cammarata and her
colleagues note, making it highly effective and especially active against Gram-positive bacteria.

The trial included 660 patients randomly assigned to intravenous delafloxacin 300 mg or vancomycin 15 mg/kg plus
aztreonam 2 g, given twice daily for five to 14 days.

Intention-to-treat analysis found a similar objective response rate, around 80%, in both groups 48 to 72 hours after
treatment. At follow-up, on day 14 of treatment, 52% of patients on delafloxacin and 50.5% of those on
vancomycin/aztreonam were cured according to investigator assessment.

At late-follow-up, on days 21-28, investigator-assessed cure rates were 70.4% and 66.6%, respectively. The rate of MRSA
eradication was 100% with delafloxacin and 98.5% with vancomycin/aztreonam.

While treatment-emergent adverse events (TEAEs) were similar between the groups, TEAEs leading to treatment
discontinuation were higher with vancomycin/aztreonam (4.3% vs. 0.9%).

The researchers conclude: With both intravenous and oral formulations, delafloxacin is appropriate for the treatment of
diverse skin infection types due to Gram-positive and -negative bacteria, including patients with MRSA.

SOURCE: http://bit.ly/2i83X8B

J Antimicrob Chemother 2017.

Reuters Health Information 2017

Cite this article: Delafloxacin an Effective Option for Acute Bacterial Skin Infections - Medscape - Oct 13, 2017.

This website uses cookies to deliver its services as described in our Cookie Policy. By using this website, you agree to the use of
cookies.
close

https://www.medscape.com/viewarticle/886993_print 1/1